| Abbreviation | Full Term |
| AFP | Alpha-fetoprotein |
| AKT | Protein kinase B |
| CEA | Carcinoembryonic antigen |
| CNI | Calcineurin inhibitor |
| CRC | Colorectal cancer |
| CRLM | Colorectal liver metastases |
| CT | Computed tomography |
| ctDNA | Circulating tumor DNA |
| DFI | Disease-free interval |
| DFS | Disease-free survival |
| ECOG | Eastern Cooperative Oncology Group |
| eGFR | Estimated glomerular filtration rate |
| FDG-PET/CT | Fluorodeoxyglucose positron emission tomography/computed tomography |
| HCC | Hepatocellular carcinoma |
| HEHE | Hepatic epithelioid hemangioendothelioma |
| LT | Liver transplantation |
| MDT | Multidisciplinary team |
| mTOR | Mammalian target of rapamycin |
| NET | Neuroendocrine tumor |
| OPTN | Organ Procurement and Transplantation Network |
| OS | Overall survival |
| PD-1 | Programmed cell death protein 1 |
| PD-L1 | Programmed death-ligand 1 |
| PI3K | Phosphoinositide 3-kinase |
| R0 | Complete (margin-negative) resection |
| RCT | Randomized controlled trial |
| SBRT | Stereotactic body radiotherapy |
| SECA | Scandinavian Exceptional Cases Allocation (trial series) |
| SiLVER | Sirolimus in Liver Transplant Recipients With Hepatocellular Carcinoma (trial) |
| STORM | Sorafenib as Adjuvant Treatment in the Prevention of HCC Recurrence (trial) |
| SUV | Standardized uptake value |
| TGF-beta | Transforming growth factor beta |
| TRANSMET | Liver Transplantation for Colorectal Cancer Liver Metastases (trial) |
| VATS | Video-assisted thoracoscopic surgery |
| VEGF | Vascular endothelial growth factor |